ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW

This is a somewhat nostalgic retro blog.  I was leafing through a book by Vince Andriole called ‘The Quinolones’.[1]  First released in 1988, its third edition is from 2000.  It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety.  It was a great review of the large and Continue reading ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW

HANTA & WHAT’S NEXT

By now, we’ve had a chance to brush up on the Hanta virus, esp. the Andes variety which caused a mini-epidemic on the arctic cruise ship MV Hondius.  Named after Hantaan, the river in South Korea where the disease first emerged, we give credit to Dr. Ho Wang Lee, the Continue reading HANTA & WHAT’S NEXT

OFF-TARGET ANTIBODIES

Quick: What do you associate with the abbreviation ‘TCR’?  Does your immunology-trained mind automatically default to ‘T-cell receptor’?  Or is your first guess ‘Tissue Cross Reactivity?  Our neural networks can deal with ambivalence and will make the right associations, eventually.  Language is imprecise by design and allows for wobble. Things Continue reading OFF-TARGET ANTIBODIES